专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130338345A1 Purification of Diphtheria Toxoid 审中-公开
标题翻译：白喉毒素的净化
公开(公告)号：US20130338345A1
公开(公告)日：2013-12-19
申请号：US13526009
申请日：2012-06-18
申请人： Seshu K. Gudlavalleti , Jeeri R. Reddy
发明人： Seshu K. Gudlavalleti , Jeeri R. Reddy
IPC分类号： C07K1/20
CPC分类号： C07K14/34
摘要： The invention disclosed is a method of purifying Diphtheria Toxoid (DT) by Hydrophobic Interaction Chromatography (HIC). The chromatographic method of the present invention provides an effective removal of contaminating glycans present in carrier protein DT and thereby provides a highly purified form of carrier protein DT for the production or preparation of polysaccharide protein conjugate vaccines.
摘要翻译：所公开的发明是通过疏水相互作用色谱法（HIC）纯化白喉毒素（DT）的方法。本发明的色谱方法提供了有效去除载体蛋白DT中存在的污染性聚糖，从而提供高纯度形式的载体蛋白DT用于生产或制备多糖蛋白质结合疫苗。

2. 发明申请

US20080020428A1 METHOD OF PRODUCING MENINGOCOCCAL MENINGITIS VACCINE FOR NEISSERIA MENINGITIDIS SEROTYPES A,C,Y, and W-135 失效
标题翻译：生产用于NEISSERIA MENINGITIDIS SEROTYPES A，C，Y和W-135的肉鸡肝炎疫苗的方法
公开(公告)号：US20080020428A1
公开(公告)日：2008-01-24
申请号：US11680471
申请日：2007-02-28
申请人： Jeeri R. Reddy
发明人： Jeeri R. Reddy
IPC分类号： C12N1/20 , C12P19/00
CPC分类号： A61K39/095 , A61K39/385 , A61K2039/55 , A61K2039/6037 , A61K2039/70 , C07K19/00
摘要： Methods for producing quadrivalent meningococcal meningitis polysaccharide and conjugate vaccines for serotypes A, C, Y and W-135 disclosed. Neisseria meningitidis fastidious medium was designed to maximize the yield of capsular polysaccharides and generate minimal cellular biomass and endotoxin in a short duration of fermentation. The crude polysaccharides are isolated, purified, and mechanically depolymerized by sonication. These purified polysaccharides were found in human clinical trials to be safe and immunogenic against meningococcal disease caused by N. meningitidis A, C, Y and W-135 serogroups in sub-Saharan Africa. In the preferred embodiment, the polysaccharides are conjugated to carrier proteins of diphtheria or tetanus toxiod to an average molecular size of 5100 to 9900 Daltons and provide broad spectrum protection to humans of all ages. Accelerated polysaccharide production and the efficacy of the resulting vaccine are demonstrated.
摘要翻译：公开了用于血清型A，C，Y和W-135的四价脑膜炎球菌性脑膜炎多糖和共轭疫苗的制备方法。设计脑膜炎奈瑟菌脑膜炎培养基以最大化荚膜多糖的产量，并在短时间的发酵中产生最小的细胞生物量和内毒素。粗多糖被分离，纯化，并通过超声处理机械解聚。在人类临床试验中发现这些纯化的多糖对撒哈拉以南非洲脑膜炎奈瑟菌A，C，Y和W-135血清群引起的脑膜炎球菌病具有安全性和免疫原性。在优选的实施方案中，多糖与白喉或破伤风毒素的载体蛋白缀合至平均分子量为5100至9900道尔顿，并为所有年龄的人类提供广谱保护。证明加速多糖生产和所得疫苗的功效。

3. 发明申请

US20100173004A1 PREVENTIVE AND THERAPEUTIC VACCINE FOR ALZHEIMER'S DISEASE 审中-公开
标题翻译：预防和治疗阿尔茨海默病的疫苗
公开(公告)号：US20100173004A1
公开(公告)日：2010-07-08
申请号：US12624613
申请日：2009-11-24
申请人： Jeeri R. Reddy
发明人： Jeeri R. Reddy
IPC分类号： A61K39/00 , A61K9/14 , A61P25/28
CPC分类号： A61K39/0007 , A61K2039/53 , A61K2039/55555
摘要： A method for producing theraputic vaccine which consist of NMDA-NRI subunit expressed in insect cells to produce recombinant protein which was encapsulated in PLGA or poly(lactide-co-glycolic acid) microparticles by solvent exchange and used for oral immunization. Excitotoxicity (i.e., a process in which an excessive amount of extracellular glutamate overexcites glutamate receptors and harms neurons) is the common cause involved in a number of neurodegenerative disorders such as Alzheimer, Parkinson, Huntington, Amyloid lateral sclerosis(ALS) and neurological conditions such as stroke, traumatic brain injury, Epilepsy. Thus the experimental model for stroke has been developed for the study of powerful N-methyl-d-aspartic acid (NMDA) NRI subunits, their protective and therapeutic potential for treatment of the neurodegenerative disorder Alzheimer's in animals and its practicability for therapy in humans.
摘要翻译：一种由昆虫细胞中表达的NMDA-NRI亚基组成的治疗性疫苗的制备方法，用于通过溶剂交换封装在PLGA或聚（丙交酯 - 共 - 乙醇酸）微粒中并用于口服免疫的重组蛋白质。兴奋性毒性（即，过量的细胞外谷氨酸盐过量表达谷氨酸受体和危害神经元的过程）是参与许多神经变性疾病如阿尔茨海默病，帕金森病，亨廷顿舞蹈症，淀粉样蛋白侧索硬化症（ALS）和神经病症的常见原因作为中风，创伤性脑损伤，癫痫。因此，研究了强力N-甲基-D-天冬氨酸（NMDA）NRI亚基的研究的实验模型，其治疗动物神经变性障碍阿尔茨海默病的保护和治疗潜力及其在人类中的实用性。

4. 发明申请

US20090175891A1 Preventive And Therapeutic Vaccine For Huntington's Disease 审中-公开
标题翻译：亨廷顿舞蹈病预防和治疗疫苗
公开(公告)号：US20090175891A1
公开(公告)日：2009-07-09
申请号：US12355787
申请日：2009-01-18
申请人： Jeeri R. Reddy
发明人： Jeeri R. Reddy
IPC分类号： A61K39/00 , A61P25/28
CPC分类号： A61K39/0007 , A61K2039/53 , A61K2039/55555
摘要： A method for producing therapeutic vaccine which consist of NMDA-NRI subunit expressed in insect cells to produce recombinant protein which was encapsulated in PLGA or poly(lactide-co-glycolic acid) microparticles by solvent exchange and used for oral immunization. Excitotoxicity (i.e., a process in which an excessive amount of extracellular glutamate overexcites glutamate receptors and harms neurons) is the common cause involved in a number of neurodegenerative disorders such as Alzheimer's, Parkinson's, Huntington's, Amyloid lateral sclerosis (ALS) and neurological conditions such as stroke, traumatic brain injury, Epilepsy. Thus the experimental model for stroke has been developed for the study of powerful N-methyl-d-aspartic acid (NMDA) NRI subunits, their protective and therapeutic potential for treatment of the neurodegenerative disorder Huntington's in animals and its practicability for therapy in humans.
摘要翻译：一种由昆虫细胞中表达的NMDA-NRI亚基组成的治疗性疫苗的制备方法，用于通过溶剂交换封装在PLGA或聚（丙交酯 - 乙醇酸）微粒中并用于口服免疫的重组蛋白质。兴奋性毒性（即，过量的细胞外谷氨酸盐过量表达谷氨酸受体和损害神经元的过程）是许多神经退行性疾病如阿尔茨海默病，帕金森病，亨廷顿舞蹈症，淀粉样蛋白侧索硬化症（ALS）和神经病症的常见原因作为中风，创伤性脑损伤，癫痫。因此，研究强大的N-甲基-D-天冬氨酸（NMDA）NRI亚基的研究的实验模型，它们在治疗动物中亨廷顿舞蹈病神经退行性疾病及其在人类治疗中的实用性的保护和治疗潜力。

5. 发明申请

US20090162387A1 PREVENTIVE AND THERAPEUTIC VACCINE FOR ALZHEIMER'S DISEASE 审中-公开
标题翻译：预防和治疗阿尔茨海默病的疫苗
公开(公告)号：US20090162387A1
公开(公告)日：2009-06-25
申请号：US12356069
申请日：2009-01-19
申请人： Jeeri R. Reddy
发明人： Jeeri R. Reddy
IPC分类号： A61K39/00
CPC分类号： A61K39/0007 , A61K2039/53 , A61K2039/55555
摘要： A method for producing therapeutic vaccine which consist of NMDA-NRI subunit expressed in insect cells to produce recombinant protein which was encapsulated in PLGA or poly(lactide-co-glycolic acid) micro particles by solvent exchange and used for oral immunization. Excitotoxicity (i.e., a process in which an excessive amount of extracellular glutamate overexcites glutamate receptors and harms neurons) is the common cause involved in a number of neurodegenerative disorders such as Alzheimer, Parkinson Huntington, Amyloid lateral sclerosis (ALS) and neurological conditions such as stroke, traumatic brain injury, Epilepsy. Thus the experimental model for stroke has been developed for the study of powerful N-methyl-d-aspartic acid (NMDA) NRI subunits, their protective and therapeutic potential for treatment of the neurodegenerative disorder Alzheimer's in animals and its practicability for therapy in humans.
摘要翻译：一种由昆虫细胞中表达的NMDA-NRI亚基组成的治疗性疫苗的制备方法，用于通过溶剂交换将其包封在PLGA或聚（丙交酯 - 乙醇酸）微粒中并用于口服免疫的重组蛋白质。兴奋性毒性（即，过量的细胞外谷氨酸盐过量表达谷氨酸受体和损害神经元的过程）是参与许多神经变性疾病如阿尔茨海默氏症，帕金森亨廷顿病，淀粉样蛋白侧索硬化症（ALS）和神经疾病如中风，创伤性脑损伤，癫痫。因此，研究了强力N-甲基-D-天冬氨酸（NMDA）NRI亚基的研究的实验模型，其治疗动物神经变性障碍阿尔茨海默病的保护和治疗潜力及其在人类中的实用性。

6. 发明申请

US20100297166A1 Meningococcal Oligosaccharide Linked Polysaccharides and Diptheria Protein Conjucate Vaccine for All Ages 有权
标题翻译：所有年龄的脑膜炎球菌寡糖连接多糖和白喉蛋白凝胶疫苗
公开(公告)号：US20100297166A1
公开(公告)日：2010-11-25
申请号：US12834532
申请日：2010-07-12
申请人： Jeeri R. Reddy
发明人： Jeeri R. Reddy
IPC分类号： A61K39/385 , A61P31/04 , C12N1/20
CPC分类号： A61K39/095 , A61K39/385 , A61K2039/55 , A61K2039/6037 , A61K2039/70 , C07K19/00
摘要： Methods for producing quadrivalent meningococcal meningitis polysaccharide and conjugate vaccines for serotypes A, C, Y and W-135 disclosed. Neisseria meningitidis fastidious medium was designed to maximize the yield of capsular polysaccharides and generate minimal cellular biomass and endotoxin in a short duration of fermentation. The crude polysaccharides are isolated, purified, and mechanically depolymerized by sonication. These purified polysaccharides were found in human clinical trials to be safe and immunogenic against meningococcal disease caused by N. meningitidis A, C, Y and W-135 serogroups in sub-Saharan Africa. In the preferred embodiment, the polysaccharides are conjugated to carrier proteins of diphtheria or tetanus toxoid to an average molecular size of 5100 to 9900 Daltons and provide broad spectrum protection to humans of all ages. Accelerated polysaccharide production and the efficacy of the resulting vaccine are demonstrated.
摘要翻译：公开了用于血清型A，C，Y和W-135的四价脑膜炎球菌性脑膜炎多糖和共轭疫苗的制备方法。设计脑膜炎奈瑟菌脑膜炎培养基以最大化荚膜多糖的产量，并在短时间的发酵中产生最小的细胞生物量和内毒素。粗多糖被分离，纯化，并通过超声处理机械解聚。在人类临床试验中发现这些纯化的多糖对撒哈拉以南非洲脑膜炎奈瑟菌A，C，Y和W-135血清群引起的脑膜炎球菌病具有安全性和免疫原性。在优选的实施方案中，多糖与白喉或破伤风类毒素的载体蛋白缀合至平均分子大小为5100至9900道尔顿，并为所有年龄的人提供广谱保护。证明加速多糖生产和所得疫苗的功效。

7. 发明申请

US20090258397A1 METHOD OF PRODUCING MENINGOCOCCAL MENINGITIS VACCINE FOR NEISSERIA MENINGITIDIS SEROTYPES A, C, Y, and W-135 审中-公开
标题翻译：生产用于NEISSERIA MENINGITIDIS SEROTYPES A，C，Y和W-135的肉鸡肝炎疫苗的方法
公开(公告)号：US20090258397A1
公开(公告)日：2009-10-15
申请号：US12212665
申请日：2008-09-18
申请人： Jeeri R. Reddy
发明人： Jeeri R. Reddy
IPC分类号： C12P19/04 , C12N1/20
CPC分类号： A61K39/095 , A61K39/385 , A61K2039/55 , A61K2039/6037 , A61K2039/70 , C07K19/00
摘要： Methods for producing quadrivalent meningococcal meningitis polysaccharide and conjugate vaccines for serotypes A, C, Y and W-135 disclosed. Neisseria meningitidis fastidious medium was designed to maximize the yield of capsular polysaccharides and generate minimal cellular biomass and endotoxin in a short duration of fermentation. The crude polysaccharides are isolated, purified, and mechanically depolymerized by sonication. These purified polysaccharides were found in human clinical trials to be safe and immunogenic against meningococcal disease caused by N. meningitidis A, C, Y and W-135 serogroups in sub-Saharan Africa. In the preferred embodiment, the polysaccharides are conjugated to carrier proteins of diphtheria or tetanus toxiod to an average molecular size of 5100 to 9900 Daltons and provide broad spectrum protection to humans of all ages. Accelerated polysaccharide production and the efficacy of the resulting vaccine are demonstrated.
摘要翻译：公开了用于血清型A，C，Y和W-135的四价脑膜炎球菌性脑膜炎多糖和共轭疫苗的制备方法。设计脑膜炎奈瑟菌脑膜炎培养基以最大化荚膜多糖的产量，并在短时间的发酵中产生最小的细胞生物量和内毒素。粗多糖被分离，纯化，并通过超声处理机械解聚。在人类临床试验中发现这些纯化的多糖对撒哈拉以南非洲脑膜炎奈瑟菌A，C，Y和W-135血清群引起的脑膜炎球菌病具有安全性和免疫原性。在优选的实施方案中，多糖与白喉或破伤风毒素的载体蛋白缀合至平均分子量为5100至9900道尔顿，并为所有年龄的人类提供广谱保护。证明加速多糖生产和所得疫苗的功效。

8. 发明申请

US20080020002A1 METHOD OF PRODUCING MENINGOCOCCAL MENINGITIS VACCINE FOR NEISSERIA MENINGITIDIS SERO TYPES A,C,Y, and W-135 审中-公开
标题翻译：生产男性男性阴道炎的方法，用于NEISSERIA MENINGITIDIS SERO类型A，C，Y和W-135
公开(公告)号：US20080020002A1
公开(公告)日：2008-01-24
申请号：US11761667
申请日：2007-06-12
申请人： Jeeri R. Reddy
发明人： Jeeri R. Reddy
IPC分类号： A61K39/095 , C12N1/20 , C12N1/38
CPC分类号： A61K39/095 , A61K39/385 , A61K2039/55 , A61K2039/6037 , A61K2039/70 , C07K19/00
摘要： Methods for producing quadrivalent meningococcal meningitis polysaccharide and conjugate vaccines for serotypes A, C, Y and W-135 disclosed. Neisseria meningitidis fastidious medium was designed to maximize the yield of capsular polysaccharides and generate minimal cellular biomass and endotoxin in a short duration of fermentation. The crude polysaccharides are isolated, purified, and mechanically depolymerized by sonication. These purified polysaccharides were found in human clinical trials to be safe and immunogenic against meningococcal disease caused by N. meningitidis A, C, Y and W-135 serogroups in sub-Saharan Africa. In the preferred embodiment, the polysaccharides are conjugated to carrier proteins of diphtheria or tetanus toxiod to an average molecular size of 5100 to 9900 Daltons and provide broad spectrum protection to humans of all ages. Accelerated polysaccharide production and the efficacy of the resulting vaccine are demonstrated.
摘要翻译：公开了用于血清型A，C，Y和W-135的四价脑膜炎球菌性脑膜炎多糖和共轭疫苗的制备方法。设计脑膜炎奈瑟菌脑膜炎培养基以最大化荚膜多糖的产量，并在短时间的发酵中产生最小的细胞生物量和内毒素。粗多糖被分离，纯化，并通过超声处理机械解聚。在人类临床试验中发现这些纯化的多糖对撒哈拉以南非洲脑膜炎奈瑟菌A，C，Y和W-135血清群引起的脑膜炎球菌病具有安全性和免疫原性。在优选的实施方案中，多糖与白喉或破伤风毒素的载体蛋白缀合至平均分子量为5100至9900道尔顿，并为所有年龄的人类提供广谱保护。证明加速多糖生产和所得疫苗的功效。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式